AlzeCure Pharma (Stockholm: ALZCUR)

Currency in SEK

Last close As at 04/02/2023


−0.18 (−3.30%)

Market capitalisation


Edison Investment Research is terminating coverage on AlzeCure Pharma. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.


Previously published reports can still be accessed via our website.

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 40.1 79.6 (32.4)
Relative 51.9 94.1 (9.4)
52 week high/low SEK7.6/SEK2.2


AlzeCure Pharma is a clinical-stage biotech company based in Sweden focused on developing innovative, small molecule drugs for the treatment of Alzheimer’s disease (symptomatic as well as disease modifying) and pain (neuropathic and osteoarthritic).

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2020A 0.0 (71.1) (71.4) (189.0) N/A N/A
2021A 0.0 (77.4) (77.8) (206.0) N/A N/A
2022E 0.0 (81.5) (81.9) (185.0) N/A N/A
2023E 0.0 (85.3) (85.6) (169.0) N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free